Lung Neuroendocrine Tumor (LNET)

Overview

Lung Neuroendocrine Tumor (LNET) is a well-differentiated neuroendocrine neoplasm of the lung (pulmonary NEN / PulNET) under Non-Small Cell Lung Cancer in OncoTree (parent: LUNG). Large cell neuroendocrine carcinoma (LUNE) is a high-grade subtype under LNET.

Cohorts in the corpus

Recurrent alterations

  • Whole-genome and transcriptome analysis of 7 metastatic pulmonary NENs confirmed recurrent MEN1, RB1, and TP53 alterations. MEN1-mutant PulNENs, unlike MEN1-mutant PanNENs, did not show large-scale LOH. PulNENs predominantly clustered in transcriptome Cluster C. Median TMB was 2.19 mut/Mb across the 28-patient NEN cohort. PMID:24326773

Subtypes

  • LUNE — Large Cell Neuroendocrine Carcinoma (high-grade, parent: LNET)

Therapeutic landscape

  • MTOR inhibitors (via MEN1 loss), somatostatin analogs (via SSTR expression), and FGFR3-directed therapy flagged as actionable in PulNEN cases via WGTA. PMID:24326773

Sources

This page was processed by crosslinker on 2026-05-09.